Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

THEOPHYLLINE ANHYDROUS

All products: not a benefit

Other products in the same Health Canada class (R03DA) — coverage varies; not interchangeable

  • Oxtriphylline (Choledyl): general benefit

Uniphyl · DIN 02014165 · 400mg · extended release tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-20 — choose a marketed DIN from the same-category list.Discontinued 2020-12-20 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Uniphyl · DIN 02014165 Manufacturer: Elvium Life Sciences; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-12-20 · brand UNIPHYL · ATC R03DA04 THEOPHYLLINE · form Tablet (extended-release) · route Oral · ingredients THEOPHYLLINE 400 MG · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Uniphyl: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16103 · Verify on the e-Formulary ↗ (DIN 02014165)

Source record
DIN 02014165: Uniphyl Raw flags: notABenefit=Y, sec3=Y Item: 860000046; group id 878; item number 2118; lccId None; manufacturer id ELV Source form: SR Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014165 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16103
Interchangeable products
Theo ER · DIN 02360101 · $0.3734
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014165
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-12-20 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (86:00 SPASMOLYTICS) and how they are covered

Matched class: 86:00 SPASMOLYTICS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: OXTRIPHYLLINE 86:00 SPASMOLYTICS

OXTRIPHYLLINE

· 1 products · General benefit · strengths: 20mg/mL · O/L

FESOTERODINE FUMARATE

· 6 products · Limited Use, codes 290 · strengths: 4mg, 8mg · Tab

MIRABEGRON

· 5 products · Limited Use, codes 290 · strengths: 25mg, 50mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:00 86:12:04 Antimuscarinics

PROPIVERINE HYDROCHLORIDE

· 1 products · Limited Use, codes 530 · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:12:04
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. INDICATIONS THEO ER (theophylline sustained release tablets) is indicated for: Symptomatic treatment of reversible bronchoconstriction associated with asthma, emphysema, chronic bronchitis and related bronchospastic disorders in patients 12 years and older. 1.1. Pediatrics Pediatrics (<12 years of age): THEO ER is not recommended for use in children under 12 years of age. 1.2. Geriatrics Geriatrics (>65 years of age): Dose Reduction may be required in elderly patients (see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS) https://pdf.hres.ca/dpd_pm/00063080.PDF PM date: September 28, 2021 Source product: THEO ER; DIN 02360101; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Uniphyl · DIN 02014165 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014165

Check this DIN again

Other review policies

For Uniphyl: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026